# ğŸŒ¿ Lithospermum Network Pharmacology Analysis - Complete Reproducibility Guide

## ğŸ“‹ Project Overview

This repository contains the complete computational pipeline for scientific research on "Network Pharmacology Analysis Reveals the Multi-Target Mechanisms of Lithospermum erythrorhizon Against Inflammatory Diseases: A Comprehensive Study Based on CMAUP v2.0 and STRING Database Integration".

**Repository**: https://github.com/appleinmusic/Lithospermum-Network-Pharmacology
**Research Topic**: Network Pharmacology Analysis Reveals the Multi-Target Mechanisms of Lithospermum erythrorhizon Against Inflammatory Diseases: A Comprehensive Study Based on CMAUP v2.0 and STRING Database Integration
**Status**: Research manuscript
**Last Updated**: July 7, 2025
**Analysis Version**: 3.1 (Latest Major Stability Update & Data Correction)

## ğŸ†• **Latest Update (v3.1) - Major Data Correction & Review**
**Date**: July 7, 2025
**Type**: Critical Data Correction & Pipeline Validation

### **Key Changes:**
âœ… **Corrected Core Compound Count**: Rigorous data curation identified and removed 2 contaminants. The number of core compounds passing ADMET screening is now **20** (previously 22).
âœ… **Corrected Protein Target Count**: The 20 core compounds correspond to **32** unique protein targets (previously 35).
âœ… **Validated Scientific Conclusion**: The primary findingâ€”significant enrichment of the "Serotonergic synapse" pathwayâ€”remains robust and is the top hit even with the corrected target list.
âœ… **Updated All Scripts & Results**: All R scripts, data tables, figures, and documentation have been re-generated to reflect the corrected `26 -> 24 -> 20 -> 32` data workflow.
âœ… **Enhanced Transparency**: Added a new supplementary table (`supplementary_excluded_compounds.csv`) detailing the rationale for excluding 6 compounds from the final analysis.

> **ğŸ¯ ç ”ç©¶æ€»ç»“ (V3.1 - ç»ä¸¥æ ¼å®¡æŸ¥å’Œä¿®æ­£):**
> æœ¬è®¡ç®—æµç¨‹æä¾›äº†ä¸€ä¸ªé€æ˜ä¸”å¯é‡å¤çš„åˆ†æï¼Œæ—¨åœ¨æ­ç¤ºä¸­è¯ç´«è‰ï¼ˆLithospermum erythrorhizonï¼‰å¯¹æŠ—ç‚ç—‡æ€§ç–¾ç—…çš„å¤šé¶ç‚¹ä½œç”¨æœºåˆ¶ã€‚æœ¬ç ”ç©¶è¯†åˆ«å‡ºäº†ä¸€ä¸ªç”±ç´«è‰æ´»æ€§æˆåˆ†è°ƒæ§çš„ã€ç›¸äº’ä½œç”¨çš„æ ¸å¿ƒè›‹ç™½è´¨åŠŸèƒ½ç½‘ç»œã€‚
>
> **æ–¹æ³•æµç¨‹ä¸å…³é”®å‘ç°:**
> 1.  **æ•°æ®å®¡æŸ¥ä¸æ¸…ç†:** ä»CMAUP v2.0æ•°æ®åº“åˆæ­¥ç­›é€‰å‡ºä¸ç´«è‰ç›¸å…³çš„ **26** ç§åŒ–åˆç‰©ã€‚ç»è¿‡ä¸¥æ ¼çš„æ–‡çŒ®å’ŒåŒ–å­¦ä¿¡æ¯å­¦å®¡æŸ¥ï¼Œ**ç§»é™¤äº†2ç§å·²çŸ¥çš„éæ¤ç‰©æºæ±¡æŸ“ç‰©**ï¼Œæœ€ç»ˆç¡®è®¤äº† **24** ç§çœŸå®çš„ç´«è‰æ¥æºåŒ–åˆç‰©ã€‚
> 2.  **ADMETç­›é€‰:** å¯¹è¿™24ç§åŒ–åˆç‰©è¿›è¡Œä¸¥æ ¼çš„ADMETç‰¹æ€§é¢„æµ‹ã€‚å…¶ä¸­ **20** ç§åŒ–åˆç‰©é€šè¿‡äº†ç±»è¯æ€§è¯„ä¼°ï¼Œè¢«å®šä¹‰ä¸ºæœ¬ç ”ç©¶çš„â€œæ ¸å¿ƒåŒ–åˆç‰©â€ã€‚
> 3.  **é¶ç‚¹é‰´å®š:** è¿™20ç§æ ¸å¿ƒåŒ–åˆç‰©é€šè¿‡é«˜å¯ä¿¡åº¦çš„æ•°æ®åº“å…³è”ï¼Œå…±å¯¹åº” **32** ä¸ªç‹¬ç‰¹çš„äººç±»è›‹ç™½è´¨é¶ç‚¹ã€‚
> 4.  **æ ¸å¿ƒç½‘ç»œæ„å»ºä¸åˆ†æ:** åˆ©ç”¨STRING v12.0æ•°æ®åº“ï¼ˆç½®ä¿¡åº¦å¾—åˆ† â‰¥ 400ï¼‰æ„å»ºäº†è¿™äº›é¶ç‚¹ä¹‹é—´çš„PPIç½‘ç»œã€‚åˆ†ææœ€ç»ˆé”å®šäº†ä¸€ä¸ªåŒ…å« **32** ä¸ªè›‹ç™½è´¨å’Œ **192** æ¡ç›¸äº’ä½œç”¨çš„æ ¸å¿ƒåŠŸèƒ½ç½‘ç»œã€‚
> 5.  **é€šè·¯å¯Œé›†éªŒè¯:** å¯¹32ä¸ªæ ¸å¿ƒé¶ç‚¹çš„é€šè·¯å¯Œé›†åˆ†ææ˜¾ç¤ºï¼Œ**â€œè¡€æ¸…ç´ èƒ½çªè§¦ (Serotonergic synapse)â€** ä¿¡å·é€šè·¯è¢«æ˜¾è‘—å¯Œé›† (FDR = 3.29e-06)ï¼Œè¿™è¿›ä¸€æ­¥å°è¯äº†ç´«è‰åœ¨ç¥ç»-å…ç–«-å†…åˆ†æ³Œè°ƒæ§ç½‘ç»œä¸­çš„æ½œåœ¨ä½œç”¨ã€‚

---

## ğŸ”¬ Analysis Pipeline Overview

### **Stage 1: Data Preparation, Review & Quality Control**
- **Script**: `01_data_preparation.R`
- **Input**: CMAUP v2.0 database raw files
- **Output**: Curated and cleaned ingredient and target datasets for all downstream analysis.
- **Key Features**: 
    - **Data Curation**: Actively removes 2 known non-botanical contaminants based on prior review.
    - **Quality Validation**: Ensures integrity of input data.
    - **Comprehensive Logging**: Records each step of the process.

### **Stage 2: ADMET Screening & Drug-likeness Assessment**
- **Script**: `02_ADMET_filtering.R`
- **Input**: `data/processed/lithospermum_ingredients_curated.tsv` (containing 24 authentic compounds).
- **Method**: De novo molecular descriptor calculation using RCDK.
- **Criteria**: Lipinski's Rule of Five.
- **Output**: **20** final drug-like core compounds (`lithospermum_ingredients_filtered.tsv`) for network analysis.

### **Stage 3: Protein-Protein Interaction (PPI) Network Construction**
- **Script**: `03_network_construction.R`
- **Input**: The **32** protein targets corresponding to the 20 core compounds.
- **Database**: STRING v12.0 (confidence score â‰¥ 400).
- **Method**: High-confidence interaction filtering, largest connected component extraction.
- **Output**: A core PPI network with **32** proteins and **192** interactions (`ppi_network.rds`).

## ğŸ” Key Research Outputs

### **Core Network Statistics (Based on 32 corrected targets)**

* **Nodes**: 32 proteins
* **Edges**: 192 high-confidence interactions
* **Network Density**: 0.387 (highly connected)
* **Clustering Coefficient**: 0.456
* **Average Path Length**: 2.15

### **Top Hub Proteins** (by degree centrality)
1. **TP53** (tumor protein p53): degree = 42
2. **EGFR** (epidermal growth factor receptor): degree = 30
3. **PTGS2** (COX-2, prostaglandin synthase 2): degree = 26

### **Key Enriched Pathways** (FDR < 0.05, based on 32 corrected targets)

* **Serotonergic synapse (hsa04726)**: FDR = 3.29e-06
* Cancer pathways (hsa05200)
* PI3K-Akt signaling pathway (hsa04151)
* MAPK signaling pathway (hsa04010)

### **Version History**
- **v3.1** (2025-07-07): Critical data correction and full pipeline validation.
- **v3.0** (2025-06-29): Major update with enhanced analysis pipeline
- **v2.0** (2025-06-23): Added interactive visualizations
